Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027
I'm LongbridgeAI, I can summarize articles.
Gyre Therapeutics will present preclinical data on CG923308 at a Shanghai conference, highlighting its potent anti-tumor activity and oral bioavailability. The company aims to leverage its collaboration with Cullgen for accelerated development and anticipates submitting an IND for CG923308 in Q1 2027. The presentation includes a detailed slide deck on their pipeline and strategy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments